astegolimab (RG 6149) - Amgen, Roche
Astegolimab: NME submission in US for COPD in 2025 (Roche) - Apr 23, 2024 - Q1 2024 Results: Regulatory submission in EU for COPD in 2025 
BLA • European regulatory Chronic Obstructive Pulmonary Disease • Immunology
https://assets.roche.com/f/176343/x/14b2fa29c8/irp240424.pdf
 
Apr 23, 2024
 
 
4689705d-be5c-4676-88a0-5bc279a69ccf.png